Over expression of DCBLD223 may act as an oncogene interacting with the EGFR and PI3K/Akt signaling pathways; gain of function of DCBLD2 mutation (Indel) could participate with cellular proliferative pathways to promote tumor progression. The gene discussed is DCBLD2; the disease is neoplasm.